Cooper Companies (COO) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Repligen (RGEN) has outperformed Cooper Companies (COO) over the past year, gaining 8.6% versus a loss of 22.7%. Over five years, RGEN leads with a -38.6% price change compared with -45.5% for COO. Repligen is the larger company by market cap ($10.40 billion vs $10.33 billion), about 1.0 times the size.
On valuation, Cooper Companies trades at a lower forward P/E (11.6x vs 61.9x for Repligen). Cooper Companies converts more of its revenue into profit, with a net margin of 9.2% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COO | RGEN |
|---|---|---|
| Share price | $54.30 | $163.84 |
| Market cap | $10.33B | $10.40B |
| 1-day change | -0.82% | -2.02% |
| YTD return | -33.75% | -0.01% |
| 1-year return | -22.72% | +8.64% |
| 5-year return | -45.47% | -38.62% |
| P/E ratio (TTM) | 18.66 | 224.44 |
| Forward P/E | 11.57 | 61.88 |
| EPS (TTM) | $2.91 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.09B | $738.26M |
| Revenue growth (YoY) | +5.06% | +16.36% |
| Net income (latest FY) | $374.90M | $48.89M |
| Gross margin | 65.54% | 52.32% |
| Operating margin | 16.69% | 7.47% |
| Net margin | 9.16% | 6.62% |
| 52-week high | $89.83 | $198.87 |
| 52-week low | $51.01 | $100.99 |
| Distance from 52-week high | -39.55% | -17.61% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +21.18% | +18.99% |
| Average volume | 3.18M | 1.18M |
| Shares outstanding | 190.16M | 63.49M |
| Employees | 15,000 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RGEN has outperformed COO by 31.4 percentage points over the past year.
- Repligen trades at a higher earnings multiple (224.4x vs 18.7x trailing P/E).
- Repligen grew revenue faster in its latest fiscal year (+16.36% vs +5.06%).
About Cooper Companies
COO stock →The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical.
Health Care · Ophthalmic Goods · 15,000 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
COO vs RGEN FAQ
Which is bigger, Cooper Companies or Repligen?
Repligen (RGEN) is larger, with a market capitalization of $10.40B compared with $10.33B for Cooper Companies (COO).
Which stock has performed better over the past year, COO or RGEN?
RGEN returned +8.64% over the past 12 months, compared with -22.72% for COO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, COO or RGEN?
COO has the lower trailing P/E at 18.7, versus 224.4 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Cooper Companies and Repligen in the same industry?
Both are in the Health Care sector, but in different industries: Ophthalmic Goods for Cooper Companies and Biotechnology: Biological Products (No Diagnostic Substances) for Repligen.